证券之星消息，7月31日动物保健板块较上一交易日下跌0.43%，大禹生物领跌。当日上证指数报收于 3573.21，下跌1.18%。深证成指报收于11009.77，下跌1.73%。动物保健板块个股涨跌见下表： 从资金流向上来看，当日动物保健板块主力资金净流出1611.97万元，游资资金净流出6281.9万元，散户 资金净流入7893.87万元。动物保健板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300871 回盛生物 | | 6787.00万 | 7.85% | -4042.91万 | -4.68% | -2744.09万 | -3.17% | | 600201 | 生物股份 | 2619.98万 | 9.14% | -534.51万 | -1.86% | -2085.47万 | -7.28% | | 002868 *ST绿康 | | 940.97万 | 10.50% | -518.20 ...

证券之星消息，7月30日动物保健板块较上一交易日下跌0.46%，生物股份领跌。当日上证指数报收于 3615.72，上涨0.17%。深证成指报收于11203.03，下跌0.77%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 871970 | 大禹生物 | 10.98 | 7.65% | 7.08万 | 7555.51万 | | | 002868 | *ST绿康 | 26.73 | 4.99% | 2.78万 | 7294.48万 | | | 839729 | 永顺生物 | 10.02 | 1.83% | 4.19万 | 4168.45万 | | | 300871 | 回盛生物 | 22.22 | 1.37% | 16.18万 | | 3.63亿 | | 002688 | 金河生物 | 7.22 | 0.84% | 42.68万 | | 3.06亿 | | 688098 | 申联生物 | 6.90 | 0.73% | 10.01万 | 6919.84 ...

证券代码：688739 证券简称：成大生物 公告编号：2025-037 辽宁成大生物股份有限公司 关于变更公司董事会秘书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、提前离任的基本情况 | 姓名 | 离任职 | 离任时 | | 原定任 | 离任 是否继续 | | 具体职务 | 是否存 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 务 | | 间 | 期到期 | 原因 | 在上市公 | | 在未履 | | | | | 日 | | 司及其控 | | 行完毕 | | | | | | | | 股子公司 | | 的公开 | | | | | | | | 任职 | | 承诺 | | | | | | | | 工作 | 董事、副 | | | | | 董事会 | | 2025 | 2026 | | | | | | | 崔建伟 | | | | 职责 是 | 总经理、 | | 否 | | | 秘书 | | 年7月 | 年5月 | | | | | | ...

天眼查商业履历信息显示，金宇生物技术股份有限公司，成立于1993年，位于呼和浩特市，是一家以从 事房地产业为主的企业。企业注册资本112036.9226万人民币，实缴资本28081.493万人民币。公司法定 代表人为张翀宇。 通过天眼查大数据分析，金宇生物技术股份有限公司共对外投资了37家企业，参与招投标项目44次，知 识产权方面有商标信息23条，此外企业还拥有行政许可2个。 来源：金融界 金融界消息 截至2025年7月29日收盘，生物股份（600201）报收于8.82元，下跌1.34%，换手率2.84%， 成交量31.84万手，成交金额2.81亿元。 资金流向方面，今日主力资金净流出1635.93万元，占比成交额5.83%。其中，超大单净流出1176.56万 元、占成交额4.19%，大单净流出459.37万元、占成交额1.64%，中单净流出流出906.48万元、占成交额 3.23%，小单净流入2542.41万元、占成交额9.06%。 生物股份最新一期业绩显示，截至2025一季报，公司营业总收入3.52亿元、同比增长1.06%，归属净利 润7648.11万元，同比减少27.57%，扣非净利润5901.56万元 ...

从资金流向上来看，当日动物保健板块主力资金净流出9984.08万元，游资资金净流出2164.17万元，散户 资金净流入1.21亿元。动物保健板块个股资金流向见下表： 证券之星消息，7月29日动物保健板块较上一交易日下跌0.5%，驱动力领跌。当日上证指数报收于 3609.71，上涨0.33%。深证成指报收于11289.41，上涨0.64%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002868 | *ST绿康 | 25.46 | 2.91% | 2.25万 | | 5731.13万 | | 688098 | 申联生物 | 6.85 | 1.33% | 10.41万 | | 7137.24万 | | 603566 | 普莱柯 | 15.23 | 0.40% | 5.03万 | | 7579.24万 | | 002688 | 金河生物 | 7.16 | 0.14% | 36.15万 | | 2.59亿 | | 688526 | 科前生物 | 17.2 ...

Core Viewpoint - The article discusses the regulatory actions taken by the Inner Mongolia Securities Regulatory Bureau against the accounting firm Zhihong and its signing accountants for inadequate audit procedures related to Jin Yu Biotechnology Co., Ltd.'s financial statements for 2023 [1][2]. Group 1: Audit Issues - The audit procedures for research and development expenses were inadequately executed, leading to incorrect capitalization timing for certain projects, and insufficient audit evidence was obtained [1][2]. - The audit procedures for long-term equity investments were also inadequately executed, particularly in the calculation of investment income from Guoyi Life Science Technology Co., Ltd. and Beijing Jiuyang Wisdom Investment Fund Management Co., Ltd., with insufficient audit evidence obtained [2]. Group 2: Regulatory Actions - The actions of the accountants violated the "Management Measures for Information Disclosure of Listed Companies," specifically Articles 45 and 46, leading to the issuance of a warning letter and recording in the securities and futures market integrity database [2][3]. - The accountants are required to submit a written report to the regulatory bureau within 30 days of receiving the decision and must adhere to relevant laws and auditing standards to improve audit quality [3].

Group 1 - The regulatory scrutiny on capital markets remains stringent, with both the auditing firm and the company being penalized for violations [1][2] - The auditing firm, Crowe Horwath, and two signing accountants faced administrative measures due to inadequate audit procedures regarding R&D expenses and long-term equity investments for the company [1] - The company, BioShares, received a warning letter from the Inner Mongolia Securities Regulatory Bureau for three major violations, including inaccurate capitalized R&D expenses and failure to disclose litigation information [2] Group 2 - BioShares reported a significant decline in financial performance for 2024, with revenue of 1.255 billion yuan, down 21.45%, and a net profit of 109 million yuan, down 61.57% [2] - The company anticipates a further decline in net profit for the first half of 2025, projecting between 57 million to 70 million yuan, a decrease of 43.05% to 53.63% year-on-year [3] - Factors contributing to the decline include increased R&D expenses for human antibody drugs, depreciation of intangible assets, intensified competition in the animal health industry, and falling product prices [3]

证券代码：600201 证券简称：生物股份 编号：临2025-047 金宇生物技术股份有限公司 关于2023年员工持股计划部分股份 回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 回购注销原因：鉴于金宇生物技术股份有限公司（以下简称"公司"）2023 年员工持股计划首次授予部分第二个解锁期公司层面业绩考核未达成、激励对象离 职，公司决定回购注销已授予但尚未解锁的权益份额对应标的股票 862.14 万股。 本次注销股份的有关情况 | 回购股份数量 | 注销股份数量 | | 注销日期 | | | | --- | --- | --- | --- | --- | --- | | 8,621,400 | 8,621,400 | 2025 | 年 7 | 月 31 | 日 | 一、本次员工持股计划回购注销的决策与信息披露 （一）公司于 2025 年 4 月 23 日召开第十一届董事会第十八次会议，审议通 过了《关于 2023 年员工持股计划第二个锁定期解锁条件未成就及回购注销部分股 票的议案》。具体内容详 ...

Group 1 - The World Health Organization warns that the Chikungunya virus is spreading globally, with 119 countries reporting cases and approximately 5.5 million people at risk of infection [1] - In Foshan, Guangdong Province, over 4,000 confirmed cases of Chikungunya have been reported, with Shunde District accounting for 3,627 cases, all of which are mild [1] Group 2 - Domestic animal health mRNA vaccines are entering a clinical boom, with recent approvals for clinical trials of mRNA vaccines for pig diarrhea and cat infectious peritonitis [2] - The rapid approval of mRNA vaccines reflects an accelerating trend in the application of mRNA technology in animal health, although the high development barriers pose risks for investors [2] Group 3 - Huaxi Bio issued a statement addressing false information circulating online, emphasizing the malicious nature of the claims and the background of the individual responsible for the misinformation [3] - The company's swift response highlights its commitment to managing reputation risks, especially in the sensitive beauty and medical aesthetics industry [3] Group 4 - Guangsheng Tang announced the successful enrollment of the first subject in the Phase III clinical trial for its innovative hepatitis B treatment, GST-HG141, marking a significant milestone in its development [4] - GST-HG141 is a novel hepatitis B core protein/capsid regulator and is the first of its kind with global intellectual property rights held by Guangsheng Tang [4]

Group 1: Company Announcements - Guangshen Railway signed a cooperation agreement for the Guangzhou East Station renovation project with a total investment of approximately 16.66 billion yuan, including a reconstruction compensation investment of about 2.228 billion yuan [1] - Fushun Special Steel announced that Ningbo Meishan Bonded Port Area Jincheng Shazhou intends to make a partial tender offer to acquire 5% of the company's shares at a price of 5.6 yuan per share [2] - China Duty Free Group reported a net profit of 2.6 billion yuan for the first half of 2025, a year-on-year decrease of 20.81%, with total operating revenue of 28.151 billion yuan, down 9.96% [3] - Gaozheng Mining announced that its controlling shareholder, Cangjian Group, reduced its shareholding by 2.76 million shares, bringing its stake down to 57.6% [4] - Sanfeng Intelligent reported that its director Chen Wei is under investigation, but the company's operations remain normal [5] - Guangsheng Group's innovative hepatitis B treatment drug GST-HG141 has successfully enrolled its first participant in a Phase III clinical trial [6] - Western Gold announced plans to acquire 100% of Xinjiang Meisheng for 1.655 billion yuan, with a premium of 1421.66% over the book value [7] - Huqin Technology announced that shareholders holding more than 5% plan to reduce their holdings by up to 4% of the company's shares [8] - Dongshan Precision's subsidiary plans to invest up to 1 billion USD in a high-end printed circuit board project [10] - Yitian Intelligent plans to jointly invest in a private equity fund focusing on artificial intelligence and computing power, with a total subscription amount of 2 billion yuan [11] - *ST Wanfang is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [12] - Ruibeka and its controlling shareholder are also under investigation by the CSRC for similar reasons [13] - BioShares' subsidiary received clinical trial approval for a cat infectious peritonitis mRNA vaccine [14] - Ruipu Bio received the first clinical trial approval for an mRNA vaccine for economic animals in China [15] - Shengke Communication announced that a major fund plans to reduce its holdings by up to 3% of the company's shares [16] - ShenKai Co. announced a capital increase of 15 million yuan in Shandong Future Robotics, a deep-sea operation robot company [18] - Shouchuang Securities plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance capital strength [19] Group 2: Financial Performance - Western Mining reported a net profit of 1.869 billion yuan for the first half of the year, a year-on-year increase of 15% [20] - Digital Certification expects a loss of 80 million to 96 million yuan for the first half of the year [21] Group 3: Major Contracts and Share Buybacks - China Communications Construction Company signed new contracts worth 991.054 billion yuan in the first half of the year, a year-on-year increase of 3.14% [22] - Zhejiang Communications Technology's subsidiary won two projects totaling over 3.4 billion yuan [23] - Feilong Co. received a notification from SAIC Motor for a designated sales agreement, expecting sales revenue of over 400 million yuan during its lifecycle [24] - Liuyuan Group plans to repurchase shares worth 100 million to 200 million yuan [25] - Meikailong's shareholders plan to reduce their holdings by no more than 3.0011% of the company's shares [26]